Chris Wolfe - 27 Jul 2021 Form 3 Insider Report for DA32 Life Science Tech Acquisition Corp.

Reporting relationship: Chief Financial Officer
Issuer ticker: N/A
Reported as of: 27 Jul 2021
Net transaction value: $0
SEC form: 3
Accepted by SEC: 27 Jul 2021, 20:08:40 UTC
Next SEC filing: 09 Aug 2021
Source filing: View source filing
Reporting owner signature: /s/ Henrikki Harsu, Attorney-in-Fact

Key filing fact

Chris Wolfe filed Form 3 for DA32 Life Science Tech Acquisition Corp. on 27 Jul 2021.

Key facts

This page summarizes Chris Wolfe's Form 3 filing for DA32 Life Science Tech Acquisition Corp..
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 Jul 2021, 20:08.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DALS holding Derivative

Class B Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 27 Jul 2021
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 143,750
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person owns 143,750 shares of Class B Common Stock which are convertible into shares of Class A Common Stock as described under the heading "Description of Securities" in the Issuer's registration statement on Form S-1 (File No. 333-257679) and have no expiration date. The shares of Class B Common Stock beneficially owned by the Reporting Person include up to 18,750 shares of Class B Common Stock subject to forfeiture to the Issuer depending on the extent to which the underwriters' over-allotment option is exercised in connection with the Issuer's initial public offering of Class A Common Stock, as described in the Registration Statement.

SEC remarks

See Exhibit 24.1 - Power of Attorney.